search

Active clinical trials for "Neoplasms, Plasma Cell"

Results 761-770 of 2666

Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma...

Multiple Myeloma

This prospective study aims to perform intra-individual comparison of the image quality between ultra-low-dose whole-body CT with deep learning reconstruction and conventional low-dose whole-body CT with iterative reconstruction in patients with suspected multiple myeloma.

Recruiting6 enrollment criteria

Myeloma Registry Platform (MYRIAM)

Multiple Myeloma

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Recruiting8 enrollment criteria

Fluciclovine PET/CT in Multiple Myeloma Patients

MyelomaMultiple1 more

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Recruiting2 enrollment criteria

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients...

Multiple Myeloma

The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.

Recruiting4 enrollment criteria

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

Multiple Myeloma

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

Recruiting7 enrollment criteria

Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With...

Multiple Myeloma

The study aims to compare the overall survival adjusted to quality of life of 2 groups of patients with multiple myeloma, depending on the type of care: (1) day hospitalization exclusively or (2) day hospitalization combined with hospital-at-home. As secondary objectives, the study aims to compare the impacts of the two types of care organization on: the survival of patients and response to treatments according to criteria of the International Myeloma Working Group, psychological status of patients, specific toxicity related to treatment used (haematological and infectious toxicity, neurotoxicity, ...), health outcomes, the caregiver's burden, This study is combined with a qualitative study about the incentives and the barriers, and in order to set up the patient's typology.

Recruiting12 enrollment criteria

GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients...

Gaucher DiseaseAcid SphingoMyelinase Deficiency

The study of splenomegaly, and the follow-up of splenectomized patients, is one of the causes of referral of these patients to pediatric gastroenterology and oncohematology clinics, and adult internal medicine and hematology. The study and management of splenomegaly is well described among the different medical specialties to which these patients arrive. After the application of the different algorithms and the different studies that are carried out, these splenomegaly are identified as being of hepatic, infectious, inflammatory, congestive, hematological origin and primary causes. Despite these studies of splenomegaly, approximately 10-15% of these patients still remain undiagnosed. Several studies have suggested that there is an increased frequency of MGUS (monoclonal gammopathy of undetermined significance) and/or multiple myeloma (MM) among Gaucher patients. Regarding ASMD (Acid Sphingomyelinase Deficiency), few studies have been published but it seems the 21% of patient with ASMD has MGUS and 15% ASMD patients have MGUS. Moreover, patients with MGUS and Gaucher disease (GD) are at increased risk of developing MM. The objective of the present study is to increase the diagnostic sensitivity of these unknown splenomegalys, or unknown splenomegaly patients with MGUS or multiple myeoloma who remain in consultations, using the usual diagnostic clinical procedures of unknown splenomegaly and unknown splenectomy patients, where we include the extraction of a blood sample for dry drop test (DBS), where the determination of the enzymatic/genetic activity will be carried out for Gaucher disease (GD) and acid sphingomyelinase deficiency (ASMD) , analysis of LisoGl1 and LisoSM.

Recruiting10 enrollment criteria

Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

Multiple Myeloma

The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose. Detecting MRD by monitoring M-protein using mass spectrometry (MS) is promising due to its high analytical sensitivity. To evaluate the correlation between MS-MRD and overall disease burden, over 60 patients with 500+ samples were identified for this study. The M-protein sequence and the patient-specific M-protein peptides of each patient were obtained by de novo protein sequencing platform using the diagnostic serum (> 30g/L). The follow- up samples were then measured by a parallel reaction monitoring (PRM) assay.

Recruiting2 enrollment criteria

Integrated Cancer Repository for Cancer Research

Pancreatic CancerThyroid Cancer48 more

The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Recruiting10 enrollment criteria

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer...

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia60 more

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting54 enrollment criteria
1...767778...267

Need Help? Contact our team!


We'll reach out to this number within 24 hrs